These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30306406)

  • 1. Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis.
    Marchesini G; Pasqualetti P; Anichini R; Caputo S; Memoli G; Ponzani P; Resi V; Rizzo M; Serviddio G; Zanette G
    Acta Diabetol; 2019 Mar; 56(3):289-299. PubMed ID: 30306406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
    Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
    Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus.
    Rydén A; Chen S; Flood E; Romero B; Grandy S
    Patient; 2017 Aug; 10(4):475-487. PubMed ID: 28315192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
    Fifer S; Rose J; Hamrosi KK; Swain D
    BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.
    Igarashi A; Bekker Hansen B; Langer J; Tavella F; Collings H; Davies N; Wyn R
    Adv Ther; 2021 Jan; 38(1):721-738. PubMed ID: 33245530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK.
    Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R
    Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient Preferences for Medications in Managing Type 2 Diabetes Mellitus: A Discrete Choice Experiment.
    Ozdemir S; Baid D; Verghese NR; Lam AY; Lee PC; Lim AY; Zhu L; Ganguly S; Finkelstein EA; Goh SY
    Value Health; 2020 Jul; 23(7):842-850. PubMed ID: 32762985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of new GLP-1 receptor agonists for type 2 diabetes.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Investig Drugs; 2016; 25(2):145-58. PubMed ID: 26587691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences.
    Mohamed AF; Zhang J; Johnson FR; Lomon ID; Malvolti E; Townsend R; Ostgren CJ; Parhofer KG
    Diabetes Metab; 2013 Oct; 39(5):397-403. PubMed ID: 23880594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A discrete choice experiment to understand preferences of patients with type 2 diabetes treated with injectable non-insulinic agents.
    Darbà J; Ascanio M
    Curr Med Res Opin; 2021 Jan; 37(1):37-43. PubMed ID: 33269944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan.
    Gelhorn HL; Bacci ED; Poon JL; Boye KS; Suzuki S; Babineaux SM
    Patient Prefer Adherence; 2016; 10():1337-48. PubMed ID: 27524889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Patients' preferences in the medicamentous treatment of diabetes mellitus type 2: A systematic classification and meta-comparison of patient preference studies].
    Mühlbacher AC; Kaczynski A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Apr; 58(4-5):452-66. PubMed ID: 25687713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK.
    Gelhorn HL; Poon JL; Davies EW; Paczkowski R; Curtis SE; Boye KS
    Patient Prefer Adherence; 2015; 9():1611-22. PubMed ID: 26635470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):633-647. PubMed ID: 28393583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
    Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
    Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
    Lovshin JA
    Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study.
    Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
    Diabetes Ther; 2017 Apr; 8(2):321-334. PubMed ID: 28155131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences.
    Mühlbacher A; Bethge S
    Eur J Health Econ; 2016 Dec; 17(9):1125-1140. PubMed ID: 26682548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.